Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to multi-agent chemotherapy and was started on ibrutinib. She had a complete response for 16 months on single-agent ibrutinib with minimal toxicity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498945PMC
http://dx.doi.org/10.1159/000477338DOI Listing

Publication Analysis

Top Keywords

richter transformation
8
ibrutinib patient
8
chronic lymphocytic
8
lymphocytic leukemia
8
stem cell
8
cell transplant
8
multi-agent chemotherapy
8
successful treatment
4
treatment richter
4
ibrutinib
4

Similar Publications

Racial Differences in the Levator Ani Muscle and Levator Hiatus in Individuals of Reproductive Age.

Am J Obstet Gynecol

December 2024

Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address:

Background: Most studies on pelvic floor muscle morphology (dimensions, shape) and its relationship with patient characteristic risk factors of pelvic floor dysfunction (demographics, medical history) have largely pertained to White individuals with vaginas. There is a need to establish normative data on pelvic floor muscle anatomy and identify morphological differences in racially diverse cohorts that may play a role in racial differences in the prevalence and pathophysiology of pelvic floor dysfunction.

Objective: (s): This study aimed to compare levator ani muscle thickness and levator hiatal morphology and their association with patient characteristics, between asymptomatic Black and White women-identifying individuals with a vagina of reproductive age.

View Article and Find Full Text PDF

Clonally unrelated HL-type RS manifested as hemophagocytic syndrome: a case report and literature review.

Front Oncol

December 2024

Department of Geriatrics, Hematology & Oncology Ward, Guangzhou First People's Hospital, Guangdong Medical University, Guangzhou, Guangdong, China.

Hodgkin lymphoma variant of Richter syndrome (HL-type RS) is a very rare disease, in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) is transformed into novel Hodgkin lymphoma. The most important prognostic factor of HL-type RS is the clonal relationship between HL-type RS and the preexisting CLL/SLL. Detailed confirmation of clonally unrelated HL-type RS cases have not been reported.

View Article and Find Full Text PDF

Background: Richter's transformation (RT) in chronic lymphocytic leukemia (CLL) is associated with poor prognosis and requires prompt modifications in patient care. CLL patients are susceptible to severe infections due to immune dysregulation induced by their malignancy and immunosuppressive therapies.

Case Presentation: We present a case of a 63-year-old man with CLL who previously achieved remission and presented with a right inguinal mass.

View Article and Find Full Text PDF

Understanding root system architecture (RSA) is essential for improving crop resilience to climate change, yet assessing root systems of woody perennials under field conditions remains a challenge. This study introduces a pipeline that combines field excavation, in situ 3-dimensional digitization, and transformation of RSA data into an interoperable format to analyze and model the growth and water uptake of grapevine rootstock genotypes. Eight root systems of each of 3 grapevine rootstock genotypes ("101-14", "SO4", and "Richter 110") were excavated and digitized 3 and 6 months after planting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!